Related Experiment Videos
[Clinical studies of ceftazidime in the pediatric field]
Insights
Ceftazidime (CAZ) showed a high efficacy rate of 79.2% in treating pediatric infections, with no observed adverse effects. This broad-spectrum antibiotic proved effective against various bacterial strains, including S. aureus and P. aeruginosa.
Area of Science:
- Pediatric Infectious Diseases
- Clinical Pharmacology
- Bacteriology
Background:
- Ceftazidime (CAZ) is a third-generation cephalosporin antibiotic with broad-spectrum activity.
- Pediatric infections require effective and safe treatment options.
Observation:
- Twenty-four pediatric patients with various infections received ceftazidime intravenously.
- Dosages ranged from approximately 149 mg/kg/day, administered in divided doses.
- Infections treated included respiratory tract, urinary tract, peritonitis, and suspected sepsis.
Findings:
- Clinical efficacy was rated excellent or good in 79.2% of patients.
- Bacteriological evaluation showed eradication of 10 out of 14 causative bacterial strains.
- Ceftazidime demonstrated effectiveness against S. aureus, P. aeruginosa, H. influenzae, K. pneumoniae, E. coli, and S. marcescens.
Implications:
- Ceftazidime is a potentially effective treatment for a range of pediatric bacterial infections.
- The favorable safety profile suggests ceftazidime can be considered for pediatric use.
- Further research could explore optimal dosing and duration for specific pediatric infections.
Abstract:
Twenty-four pediatric patients with infections were treated with ceftazidime (CAZ) by one-shot intravenous injection in the doses of 39 approximately 149 mg/kg/day in 4 divided doses as a rule. These patients' ages ranged from 2 months to 13 years 4 months. The duration of the administration ranged from 4 to 19 days, and total doses ranged from 1.38 to 57 g. Infections consisted of respiratory tract infections in 19 cases (acute tonsillitis in 3, acute bronchitis in 7, and pneumonia in 9), urinary tract infection in 1 case, acute peritonitis in 1 case, and suspected sepsis in 3 cases. Clinical efficacy was excellent in 18, good in 1, fair in 1, and poor in 4 cases, and the efficacy rate (excellent + good) was 79.2%. Bacteriological response was evaluated on 14 strains of bacteria isolated from lesions, assumed as the causative organisms (7 strains of S. aureus, 3 of P. aeruginosa, 1 of H. influenzae, 1 of K. pneumoniae, 1 of E. coli, and 1 of S. marcescens). Out of these strains, 10 were eradicated, and 1 (P. aeruginosa) decreased, but 2 strains (both S. aureus) persisted. (One strain of S. aureus was not examined.) No adverse effect suspected to be related to the drug was observed either in subjective symptom or in objective findings.